ABSTRACT

In osteoarthritis treatment, chondroprotectors are prescribed, the purpose of which is to stop the destruction of the cartilage structure during the progression of the disease. But not all drugs that belong to the chondroprotectors group have the proper qualities: there is a standardized active substance in the composition, there are studies to evaluate pharmacokinetics, there is a valid code in the anatomical-therapeutic-chemical classification of the WHO (at Dec 27,2024), medicinal product has both symptomatic and structurally modifying effects, only a long course is effective. therapy. Standardized active substance include chondroitin sulfate: it has a standardized active substance, studied pharmacokinetics, is present in the international classification of anatomical-therapeutic-chemical, and has a high level of proven efficacy with prolonged use due to its symptomatic and structural effects.

KEYWORDS: osteoarthritis, lower back pain, chondroprotectors, chondroitin sulfate, Chondroguard, symptomatic slow acting drugs for osteoarthritis, disease-modifying osteoarthritis drugs

For citation: Romanov I.D., Shavlovskaya O.A., Bokova I.A.  Comparative Evaluation of Parenteral Chondroprotectors. Comorbidity Neurology. 2025; 2 (2): 45-53. https://doi.org/10.62505/3034-185x-2025-2-2-45-53

For correspondence: Olga A. Shavlovskaya, Dr. Sci. (Med.), Professor, Chair of Organization of Medical Rehabilitation and Sanatorium Treatment, International University of Restorative Medicine, Moscow, Russia, e-mail: shavlovskaya@1msmu.ru

REFERENCES

1.Akkoc N., van der Linden S., Khan M.A. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. Best Pract Res Clin Rheumatol. 2006; 20 (3): 539-557. https://doi.org/10.1016/j.berh.2006.03.003

2.Shavlovskaya O.A., Gromova О.А., Kochish A.Yu., et al. Disease-modifying osteoarthritis drugs (DMOADs): new trends in osteoarthritis therapy. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023; 16 (3): 482-499. https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.207 (In Russ.)

3.Bruyere O., Honvo G., Veronese N., et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019; 49 (3): 337-350. https://doi.org/10.1016/j.semarthrit.2019.04.008

4.Pavelka K., Gatterova J.V., Gollerova V., et al. A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon) as a structure modifying therapy in osteoarthritis of the hip and knee. Osteoarthritis Cartilage. 2000; 8 (5): 335-342. https://doi.org/10.1053/joca.1999.0307

5.Berg P.A., Kaboth U., Becker E.W., Klein R. The analysis of a severe side effect of a cartilage-protective agent by immunological studies. Dtsch Med Wochenschr. 1992; 117 (42): 1589-1593. https://doi.org/10.1055/s-2008-1062480

6.Gromova O.A., Torshin I.Yu., Lila A.M., et al. Systematic study review on antitumor effects of glucosamine and chondroitin sulfate cartilage protectors. RMJ. Medical Review. 2019; 4 (I): 4-10 (In Russ.)

7.Анатомо-терапевтическо-химическая (АТХ) система классификации с установленными суточными дозами. Всемирная Организация Здравоохранения; 12.27.2024. Доступно по: https://atcddd.fhi.no/atc_ddd_index 05.04.2025 (In Russ.)

8.Shavlovskaya O.A. Comparative analysis of drugs with chondroprotective effect: a review. Comorbidity Neurology. 2025; 2 (1): 49-55. https://doi.org/10.62505/3034-185x-2025-2-1-49-55  (In Russ.)

9.Kolasinski S., Neogi T., Hochberg M., et al. 2019 American College of Rheumatology. Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020; 72 (2): 149-62. https://doi.org/10.1002/acr.24131

10.Kloppenburg M., Kroon F., Blanco F., et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019; 78 (1): 16-24. https://doi.org/10.1136/annrheumdis-2018-213826

11.Smolen J., Landewe R., Bijlsma J., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020; 79 (6): 685-99. https://doi.org/10.1136/annrheumdis-2019-216655

12.Geenen R., Overman C.L., Christensen R., et al. EULAR recommendations for the health professional’s approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018; 77 (6): 797-807. https://doi.org/10.1136/annrheumdis-2017-212662

13.Moseng T., Vliet Vlieland T.P.M., Battista S., et al. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update. Ann Rheum Dis. 2024; 83 (6): 730-740. https://doi.org/10.1136/ard-2023-225041

14.Arden N.K., Perry T.A., Bannuru R.R., et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nature Reviews Rheumatology. 2020; 17 (1): 59-66. https://doi.org/10.1038/s41584-020-00523-9 

15.Torshin I.Yu., Gromov А.N., Gromova O.A. Computational linguistics and sentiment analysis of misconceptions in pharmacotherapy of osteoarthritis pain. Epilepsy and Paroxysmal Conditions. 2023; 15 (3): 294-308. https://doi.org/10.17749/2077-8333/epi.par.con.2023.164 (In Russ.)

16.Gromova O.A., Torshin I.Yu., Zaychik B.T. et al. Differences in the standardization of medicinal products based on extracts of chondroitin sulfate. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021; 14 (1): 50-62. https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.083 (In Russ.)

17.Shavlovskaya OA, Gromova ОА, Torshin IYu, Romanov ID. From misconceptions to reasonable osteoarthritis patients therapy. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023; 16 (2): 317-330. https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.183 (In Russ.)

18.Morita M., Yamada K., Date H., et al. Efficacy of chondroitin sulfate for painful knee osteoarthritis: a one-year, randomized, double-blind, multicenter clinical study in Japan. Biological and Pharmaceutical Bulletin. 2018; 41 (2): 163-171. https://doi.org/10.1248/bpb.b17-00556

19.Richy F., Bruyere O., Ethgen O., et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis. Archives of Internal Medicine. 2003; 163 (13): 1514.  https://doi.org/10.1001/archinte.163.13

20.Railhac J.J., Zaim M., Saurel A.S., et al. Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: a randomized, double-blind, placebo-controlled pilot study using MRI. Clinical Rheumatology. 2012; 31 (9): 1347-1357. https://doi.org/10.1007/s10067-012-2022-4

21.Torshin I.Yu., Lila A.M., Naumov A.V. et al. Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020; 13 (4): 388-399. https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.066 (In Russ.)

22.Simental-Mendia M., Sanchez-Garcia A., Vilchez-Cavazos F. et al. Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials. Rheumatology International. 2018; 38 (8): 1413-1428. https://doi.org/10.1007/s00296-018-4077-2

23.Rabade A., Viswanatha G., Nandakumar K, Kishore A. Evaluation of efficacy and safety of glucosamine sulfate, chondroitin sulfate, and their combination regimen in the management of knee osteoarthritis: a systematic review and meta-analysis. Inflammopharmacology. 2024; 32 (3): 1759-1775. https://doi.org/10.1007/s10787-024-01460-9

24.Рубрикатор клинических рекомендаций. Коксартроз. 2024. URL: https://cr.minzdrav.gov.ru/preview-cr/870_1 (дата обращения 24.04.2025).

25.Рубрикатор клинических рекомендаций. Гонартроз. 2024. URL: https://cr.minzdrav.gov.ru/preview-cr/868_1 (дата обращения 24.04.2025).

26.Hochberg M.C. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage. 2010; 18 (Suppl 1): 28-31. https://doi.org/10.1016/j.joca.2010.02.016

27.Yang W., Sun C., He S.Q. et al. The efficacy and safety of diseasemodifying osteoarthritis drugs for knee and hip osteoarthritis systematic review and network meta-analysis. J Gen Intern Med. 2021; 36 (7): 2085-2093. https://doi.org/10.1007/s11606-021-06755-z

28.Oo W.M., Hunter D.J. Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs). Ther Adv Musculoskel Dis. 2022; 14: 1759720X221090297. https://doi.org/10.1177/1759720X221090297

29. Shavlovskaya OA, Romanov I.D., Bokova I.A. Retrospective comparative analysis of chondroprotective therapy effectiveness in chronic lower back pain patients. Comorbidity Neurology. 2024; 1 (3): 45-53. https://doi.org/10.62505/3034-185x-2024-1-3-45-53 (In Russ.)

30. Sarvilina I.V., Galustyan A.N., Hadzhidis A.K., et al. Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2019; 12 (4): 255-266. https://doi.org/10.17749/2070-4909.2019.12.4.255-266 (In Russ)

31.Sarvilina I.V., Danilov A.B. Comparative analysis of the use of symptomatic slow acting drugs for osteoarthritis containing chondroitin sulfate or affecting its biosynthesis in patients with non-specific low back pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2023; 123 (1): 81-96. https://doi.org/10.17116/jnevro202312301181 (In Russ)

32.Sarvilina I.V., Danilov A.B. Comparative analysis of the use of symptomatic slow acting drugs for osteoarthritis containing chondroitin sulfate or affecting its biosynthesis in patients with non-specific low back pain. S.S. Korsakov Journal of Neurology and Psychiatry. 2023; 123 (1): 81–96. https://doi.org/10.17116/jnevro202312301181 (In Russ.)

33.Minasov T.B., Lila A.M., Nazarenko A.G., et al. Morphological reflection of highly purified chondroitin sulfate action in patients with decompensated form of knee osteoarthritis. Modern Rheumatology Journal. 2022; 16 (6): 55-63. https://doi.org/10.14412/1996-7012-2022-6-55-63 (In Russ.)

34.Sarvilina I.V., Minasov T.B., Lila A.M. et al. On the efficacy of the parenteral form of highly purified chondroitin sulfate in the mode of perioperative preparation for total knee arthroplasty. RMJ. 2022; 7: 7-16. (In Russ.)

35.Minasov T.B., Sarvilina I.V., Lila A.M., et al. Subchondral bone remodeling and angiogenesis in decompensated osteoarthritis: evolution of therapeutic targeting. RMJ. 2023; 8: 8-14. (In Russ.)

ADDITIONAL INFORMATION

Igor D. Romanov, Neurologist, Chief specialist of the Department of Methodological Support of additional professional education programs, International University of Restorative Medicine, Moscow, Russia. E-mail: romanov@1msmu.ru. ORCID: https://orcid.org/0009-0003-0874-2834

Olga A. Shavlovskaya, Dr. Sci. (Med.), Professor, Chair of Organization of Medical Rehabilitation and Sanatorium Treatment, University of Restorative Medicine, Moscow, Russia. E-mail: shavlovskaya@1msmu.ru. ORCID: https://orcid.org/0000-0003-3726-0730

Irina A. Bokova, PhD. Sci. (Med.), Associate Professor, Chair of Restorative Medicine, Rehabilitation and Balneology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. ORCID: https://orcid.org/0000-0002-1640-1605

Author contributions. All authors confirm that their authorship complies with the international ICMJE criteria (all authors made a significant contribution to the development of the concept, the conduct of the study and the preparation of the article, read and approved the final version before publication). Special contributions: Shavlovskaya O.A. - conceptualization; Romanov I.D., Shavlovskaya O.A., Bokova I.A. - formal analysis,  writing – original draft; writing – review & editing

Funding. This study was not supported by any external sources of funding.

Disclosure. The authors declare no apparent or potential conflicts of interest related to the publication of this article.

The content is available under the Creative Commons Attribution 4.0 License.

©2025. Igor D. Romanov, Olga A. Shavlovskaya, Irina A. Bokova